In a context of rapid growth and expansion into new markets, MB Therapeutics is structuring its development by onboarding a Chief Business Officer (CBO) to its executive team.

This key role aims to accelerate the company's commercial expansion, both domestically and internationally, by strengthening ties with hospital partners, industry players, health startups, and key actors in the CDMO (Contract Development and Manufacturing Organization) sector.

An experienced profile to support this momentum

With 15 years of experience in the pharmaceutical industry, he has held executive positions within a CDMO (Contract Development and Manufacturing Organization) specializing in industrial contract manufacturing, notably at Fareva. This career path has allowed him to develop an operational vision of production requirements, a strong culture of quality, as well as an in-depth understanding of the commercial and partnership dynamics within the pharmaceutical sector.

He also has genuine, recognized expertise in establishing sustainable strategic partnerships with pharmaceutical companies, healthcare institutions, and healthcare innovation players.

Structuring geographic and partnership development

As CBO, Matthieu plays a central role in the international expansion and reinforcement of MB Therapeutics' business model. He drives the roll-out of the MB model, contributes to sales growth, and structures strategic partnerships, both in France and abroad.

His arrival comes at a key moment in the company's growth, within an already established dynamic. This new momentum injected into the executive team reflects a clear ambition: to structure our commercial development, accelerate ongoing projects, and prepare the next stages of our national and international deployment.

A strategic step

The arrival of this new role marks a strategic step in the evolution of MB Therapeutics. It embodies our desire to build a robust, open, and collaborative organization, while preserving the agility and innovation that make us unique in the market.

We wish Matthieu every success in his new role.